Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis of Mature (EMM) vs. Immature (baseline) iPSC-aCM compared to human atrial tissue (HAT) obtained from the same patient.

ABSTRACT: RNA-seq analysis of Mature (EMM) vs. Immature (baseline) iPSC-aCM compared to human atrial tissue (HAT) obtained from the same patient.

PROVIDER: PRJNA798103 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17648500_1.fastq.gz	Fastqsanger.gz
	SRR17648500_2.fastq.gz	Fastqsanger.gz
	SRR17648501_1.fastq.gz	Fastqsanger.gz
	SRR17648501_2.fastq.gz	Fastqsanger.gz
	SRR17648502_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

RNA-seq analysis of Mature (EMM) vs. Immature (baseline) iPSC-aCM compared to human atrial tissue (HAT) obtained from the same patient.

Project description:The goal of this experiment is to identify gene ontology pathways and differentially expressed genes that distinguish mature iPSC-aCM, immature iPSC-aCM, and human atrial tissue derived from the same patient.

2022-04-05 | GSE193856 | GEO

nucleosome profiles 972 EMM

Project description:nucleosome profiles 972 EMM

| PRJEB21376 | ENA

Transcriptional profiling to compare gene expression in supraorbital mesenchyme (SOM) and early migration mesenchyme (EMM) of wild type mouse embryos

Project description:During embryonic development, the mesenchyme surrounding the brain (cranial mesenchyme) gives rise to several structures such as the meninges, calvaria, and the dermis of the scalp. It has been known that the two regions within the cranial mesenchyme, namely, SOM on the basolateral side and EMM on the apical side of the head, have different developmental fates. However, the molecular genetic basis underlying this difference had been unclear. To address this question, we sought to identify genes differentially expressed between EMM and SOM. Through RNAseq, we identified 1095 genes with higher expression in EMM than in SOM, and 398 genes with higher expression in SOM than in EMM (fold change>2, p<0.001, base mean count>50).

2019-08-03 | GSE128379 | GEO

Omics analyses of stromal cells from ACM patients reveal alterations in chromatin organization and mitochondrial homeostasis [Bisulfite-Seq]

Project description:Arrhythmogenic cardiomyopathy (ACM) is a genetic disorder, characterized by ventricular ar-rhythmias, contractile dysfunctions and fibro-adipose replacement of the myocardium. Cardiac mesenchymal stromal cells (CMSC) participate to disease pathogenesis by differentiating towards adipocytes and myofibroblasts. Some altered pathways in ACM are known, but many are yet to be discovered. In order to define changes in the gene expression profiles between ACM- and HC-CMSC, we performed a high throughput Bisulfite-seq on 6 ACM and 6 HC samples. Out of 12466 expressed peaks, 30 resulted differentially expressed. Through enrichment and gene network analyses, we identified differentially regulated pathways, some of which never associated with ACM, including mitochondrial functioning and chromatin organization. Functional validations confirmed that ACM-CMSC exhibited a higher amount of active mitochondria and ROS production, a lower proliferation rate and a more pronounced epicardial-to-mesenchymal transition, compared to controls. In conclusion, ACM-CMSC -omics revealed some additional altered molecular pathways, relevant in the disease pathogenesis, which may constitute novel targets for specific therapies.

2024-06-30 | GSE234183 | GEO

Omics analyses of stromal cells from ACM patients reveal alterations in chromatin organization and mitochondrial homeostasis [RNA-Seq]

Project description:Arrhythmogenic cardiomyopathy (ACM) is a genetic disorder, characterized by ventricular ar-rhythmias, contractile dysfunctions and fibro-adipose replacement of the myocardium. Cardiac mesenchymal stromal cells (CMSC) participate to disease pathogenesis by differentiating towards adipocytes and myofibroblasts. Some altered pathways in ACM are known, but many are yet to be discovered. In order to define changes in the gene expression profiles between ACM- and HC-CMSC, we performed a high throughput RNA-seq on 6 ACM and 6 HC samples. Out of 15031 expressed genes, 529 resulted differentially expressed. Through enrichment and gene network analyses, we identified differentially regulated pathways, some of which never associated with ACM, including mitochondrial functioning and chromatin organization. Functional validations confirmed that ACM-CMSC exhibited a higher amount of active mitochondria and ROS production, a lower proliferation rate and a more pronounced epicardial-to-mesenchymal transition, compared to controls. In conclusion, ACM-CMSC -omics revealed some additional altered molecular pathways, relevant in the disease pathogenesis, which may constitute novel targets for specific therapies.

2024-06-30 | GSE233780 | GEO

Expression data from different grades (WHO) of astrocytomas (ACM)

Project description:The aim of the study was to identify significant alterations in genes and molecular functional pathways in comparison with normal and ACM tissue, and detect the marker genes to differentiate the different stage astrocytomas Total RNA was isolated from Seventeen tumor tissue of patients, which included two WHO grade I(T1) and five WHO grade II(T2), III(T3) and IV(T4) samples, and four pooled normal tissue samples. The genome-wide expression analysis was first performed by directly comparing the expression profile of highly enriched different grade astrocytomas and pooled normal tissues, we then applied various data-mining methods to process the 15 different grades tumor tissues sample. Paired T-test and Q-cluster method was performed to explore mark genes validated by qRT-PCR. This study utilized a pathway-specific enrichment analysis of the microarray data and quantified the gene expression difference between astrocytomas tumor and pooled normal tissues. BioCarta and KEGG pathways of the ACM compared to normal tissue were identified through enrichment tests on gene lists obtained using SAM, while GO is organized into hierarchical annotations in the context of normal cellular function, the BioCarta and KEGG database organizes the genes(gen products) into pathway reaction maps and functional complexes, including some disease-specific pathway

2010-01-05 | E-GEOD-19728 | biostudies-arrayexpress

Expression data from different grades (WHO) of astrocytomas (ACM)

2010-01-05 | GSE19728 | GEO

Mucin 1 knockdown in EMM myeloma cells

Project description:Mucin 1 knockdown in EMM myeloma cells

| PRJNA472976 | ENA

Pseudoduganella chitinolytica isolate:ACM 3522T

Project description:Telluria chitinolytica ACM 3522T

| PRJNA938762 | ENA

Expression profile of melanoma cells following p300 HAT inhibition

Project description:Epigenetic events, including covalent post-translational modification of histones, have frequently been demonstrated to play critical roles in tumor development and progression. The transcriptional coactivator, p300/CBP, possesses both histone acetyltransferase (HAT) activity as well as scaffolding properties that directly influence transcriptional activation of targeted genes. We have used a recently reported small molecule inhibitor of p300 HAT activity, C646, to explore the specific contribution of p300/CBP HAT activity to tumor development and progression. We find that C646 inhibits the growth of lineage-specific tumor cell lines including human melanomas through direct transcriptional regulation of cell cycle regulatory proteins. Further evaluation of the p300 HAT transcriptome in human melanoma cells using comprehensive gene expression profiling reveals that p300 HAT activity globally promotes cell cycle progression, nucleosome assembly, and the DNA damage checkpoint through direct transcriptional regulatory mechanisms. Additionally, C646 promotes sensitivity to DNA damaging agents leading to enhanced apoptosis of melanoma cells following combination treatment with cisplatin. Together our data suggest that p300 HAT activity regulates critical growth regulatory pathways in tumors and may serve as a novel therapeutic target for melanoma and other malignancies by promoting cellular responses to DNA damaging agents. Keywords: p300, small molecule inhibitor, melanoma

2013-08-01 | GSE45981 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data